|
24.04.2017 22:03:00
|
Sangamo Therapeutics Announces Participation In The ARM 5th Annual Cell & Gene Therapy Investor Day
RICHMOND, Calif., April 24, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, announced today that Dr. Sandy Macrae, Sangamo's chief executive officer, will provide a corporate overview at the Alliance for Regenerative Medicine's 5th Annual Cell & Gene Therapy Investor Day on Thursday, April 27th at 2:30 p.m. Eastern Time. The meeting is being held in Boston, MA.
The presentation and discussion will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investor Relations section under Events and Presentation. A live video webcast of the presentation will also be available at http://www.arminvestorday.com/webcast. The presentation will be archived on the Sangamo website for two weeks once the replay of the event is available.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the company's industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. For more information about Sangamo, visit the Company's website at www.sangamo.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sangamo-therapeutics-announces-participation-in-the-arm-5th-annual-cell--gene-therapy-investor-day-300444504.html
SOURCE Sangamo Therapeutics, Inc.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Sangamo Therapeutics Incmehr Nachrichten
|
16:03 |
Schwache Performance in New York: NASDAQ Composite fällt zum Handelsstart (finanzen.at) | |
|
17.12.24 |
NASDAQ-Handel NASDAQ Composite verliert schlussendlich (finanzen.at) | |
|
17.12.24 |
NASDAQ Composite Index-Papier Sangamo Therapeutics-Aktie: So viel Gewinn hätte ein Investment in Sangamo Therapeutics von vor einem Jahr abgeworfen (finanzen.at) | |
|
16.12.24 |
Optimismus in New York: Letztendlich Pluszeichen im NASDAQ Composite (finanzen.at) | |
|
16.12.24 |
NASDAQ Composite aktuell: So entwickelt sich der NASDAQ Composite am Montagnachmittag (finanzen.at) | |
|
16.12.24 |
Pluszeichen in New York: Anleger lassen NASDAQ Composite am Mittag steigen (finanzen.at) | |
|
16.12.24 |
Handel in New York: Zum Start Gewinne im NASDAQ Composite (finanzen.at) | |
|
13.12.24 |
Optimismus in New York: NASDAQ Composite letztendlich mit Zuschlägen (finanzen.at) |
Analysen zu Sangamo Therapeutics Incmehr Analysen
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.